Done. Characterization of Two Novel Oncogenic FGFR2 Fusions Sensitive to the FGFR Selective Inhibitor Debio 1347 in Cholangiocarcinoma - Debiopharm
Home Drug development Publications Characterization of Two Novel …

Characterization of Two Novel Oncogenic FGFR2 Fusions Sensitive to the FGFR Selective Inhibitor Debio 1347 in Cholangiocarcinoma

Presented at AACR 2015, Philadelphia, US

A Vaslin, S Rigotti, G Vuagniaux, C Moulon, H Tanaka

Debiopharm International SA, Switzerland